Skip to content

Extended Fragrance Ingredients Surveillance Study (EFISS) - Surveillance Study to Monitor the Frequency of Contact Allergy to a Defined Group of Fragrance Ingredients with a View to Providing Reliable Information onTrends

Extended Fragrance Ingredients Surveillance Study (EFISS) - Surveillance Study to Monitor the Frequency of Contact Allergy to a Defined Group of Fragrance Ingredients with a View to Providing Reliable Information onTrends - Extended Fragrance Ingredients Surveillance Study (EFISS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56979
Enrollment
900
Registered
2024-08-26
Start date
2024-10-01
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergie contact dermatitis contact eczema

Interventions

None listed

Sponsors

IFRA (International Fragrance Association)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Dermatitis patents, 18 years or older who are eligible for a diagnostic patch test

Exclusion criteria

Exclusion criteria: Apart from excluding children and adolescence below 18 years of age at 4 weeks before testing, no specific exclusion criteria other than those covered by the ESCD guidelines (European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice, 2015) are to be considered.

Design outcomes

Primary

MeasureTime frame
The results of the epicutaneous patch test which are assessed according to international guidelines, International Contact Dermatitis Research Group (ICDRG). The reactions are qualified as -, positive (+), strongly positive (++), extremely positive (+++), negative (-), doubtful (?), irritation (ir)

Secondary

MeasureTime frame
Data on intra- and inter-clinical variations with the aim of reducing them.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)